Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERO NASDAQ:NMTR NASDAQ:ONCO NASDAQ:PTIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$0.03-3.1%$0.03$0.02▼$26.99$1.14M0.21541,416 shs36,958 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shsN/AONCOOnconetix$0.37-8.2%$1.86$0.36▼$74.29$240K3.015.38 million shs323,522 shsPTIXAtrinsic$0.58$0.60$0.25▼$14.28$1.05M1.1342,748 shs2,868 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics-4.75%+1.90%-2.13%-33.13%-99.77%NMTR9 Meters Biopharma0.00%0.00%0.00%+66.67%-99.31%ONCOOnconetix-10.22%-41.83%-68.68%-93.09%-98.63%PTIXAtrinsic+5.45%-34.09%+9.43%+45.00%-80.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$0.03-3.1%$0.03$0.02▼$26.99$1.14M0.21541,416 shs36,958 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shsN/AONCOOnconetix$0.37-8.2%$1.86$0.36▼$74.29$240K3.015.38 million shs323,522 shsPTIXAtrinsic$0.58$0.60$0.25▼$14.28$1.05M1.1342,748 shs2,868 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics-4.75%+1.90%-2.13%-33.13%-99.77%NMTR9 Meters Biopharma0.00%0.00%0.00%+66.67%-99.31%ONCOOnconetix-10.22%-41.83%-68.68%-93.09%-98.63%PTIXAtrinsic+5.45%-34.09%+9.43%+45.00%-80.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEROCERo Therapeutics 1.67Reduce$45.00144,594.53% UpsideNMTR9 Meters Biopharma 0.00N/AN/AN/AONCOOnconetix 1.00SellN/AN/APTIXAtrinsic 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ONCO, CERO, NMTR, and PTIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026ONCOOnconetix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEROCERo TherapeuticsN/AN/AN/AN/A($41.98) per shareN/ANMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/AONCOOnconetix$815.37K0.30N/AN/A$50.53 per share0.01PTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEROCERo Therapeutics-$8.30M-$102.61N/AN/AN/AN/AN/A-209.40%6/3/2026 (Estimated)NMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/AONCOOnconetix-$14.03M-$216.73N/AN/AN/A-1,717.50%8.24%2.90%5/11/2026 (Estimated)PTIXAtrinsic-$5.53M-$3.45N/AN/AN/AN/AN/A-379.72%5/11/2026 (Estimated)Latest ONCO, CERO, NMTR, and PTIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/ACEROCERo Therapeutics-$0.8004N/AN/AN/AN/AN/A5/11/2026N/APTIXAtrinsic-$4.48N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCEROCERo TherapeuticsN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEROCERo TherapeuticsN/A0.560.56NMTR9 Meters BiopharmaN/A0.590.59ONCOOnconetixN/A0.660.65PTIXAtrinsicN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEROCERo Therapeutics29.64%NMTR9 Meters Biopharma22.34%ONCOOnconetix23.89%PTIXAtrinsic7.97%Insider OwnershipCompanyInsider OwnershipCEROCERo Therapeutics0.36%NMTR9 Meters Biopharma2.40%ONCOOnconetix0.27%PTIXAtrinsic8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEROCERo Therapeutics836.79 million1.05 millionN/ANMTR9 Meters Biopharma2014.34 million13.99 millionNo DataONCOOnconetix12656,000654,000N/APTIXAtrinsic21.81 million1.78 millionNot OptionableONCO, CERO, NMTR, and PTIX HeadlinesRecent News About These CompaniesProtagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114April 23, 2026 | accessnewswire.comAProtagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114March 17, 2026 | accessnewswire.comAAtrinsic (NASDAQ:PTIX) Shares Up 10.9% – Should You Buy?March 4, 2026 | defenseworld.netDResults from Phase 1 Multiple-Dose Study of PT00114December 9, 2025 | accessnewswire.comAProtagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance NoticeNovember 27, 2025 | accessnewswire.comAAtrinsic (NASDAQ:PTIX) Trading Up 2.5% – Time to Buy?November 22, 2025 | defenseworld.netDProtagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD StudyNovember 13, 2025 | accessnewswire.comAProtagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq ComplianceAugust 22, 2025 | accessnewswire.comAProtagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood DisordersAugust 21, 2025 | accessnewswire.comAProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | prismmediawire.comPProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | globenewswire.comProtagenic Therapeutics, Inc. (PTIX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comProtagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comProtagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comProtagenic Therapeutics and Phytanix merge in all stock dealMay 21, 2025 | thepharmaletter.comTProtagenic Therapeutics Receives $3.1 Million from Recent Warrant ActivityMay 21, 2025 | accessnewswire.comAProtagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comProtagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely BullishMay 20, 2025 | msn.comProtagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma FirmMay 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026Abbott Stock Crash: Rebound Could Be Coming FastBy Thomas Hughes | April 17, 2026ONCO, CERO, NMTR, and PTIX Company DescriptionsCERo Therapeutics NASDAQ:CERO$0.03 0.00 (-3.12%) As of 10:57 AM EasternCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Onconetix NASDAQ:ONCO$0.37 -0.03 (-8.17%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Atrinsic NASDAQ:PTIX$0.58 0.00 (0.00%) As of 05/7/2026 02:44 PM EasternProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
